



I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 26, 2006    Signature: *Robbin Graffius*  
 (Robbin Graffius)

Docket No.: 0107070.00129US1  
 (PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Gregor CEVC et al.                      Confirmation No.: 1865  
 Application No.: 09/890,371                      Art Unit: 1646  
 Filed: April 8, 2002                      Examiner: Bruce D. Hissong  
 Title: TRANSNASAL TRANSPORT/IMMUNISATION WITH HIGHLY ADAPTABLE CARRIERS

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Dear Sir:

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Respectfully submitted,

Dated: October 26, 2006

*Emily R. Whelan*  
 \_\_\_\_\_  
 Emily R. Whelan  
 Registration No.: 50,391  
 Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP  
 60 State Street  
 Boston, Massachusetts 02109  
 (617) 526-6000 (telephone)  
 (617) 526-5000 (facsimile)

10/30/2006 BABRAHA1 00000054 080219 09890371  
 01 FC:1806                      180.00 DA



Substitute for form 1449/PTO			<i>Complete if Known</i>	
			Application Number	09/890,371
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>			Filing Date	April 8, 2002
			First Named Inventor	Gregor CEVC
			Art Unit	1646
			Examiner Name	Bruce D. Hissong
			Attorney Docket Number	0107070.00129US1
Sheet	1	of	2	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-6,165,500	12-26-2000	Cevc et al.	
	AB*	US-6,248,329	06-19-2001	Chandrashekar et al.	
	AC*	US-20020048596-A1	04-25-2002	Cevc et al.	
	AD	US-09/890,335	07-26-2001	Cevc et cl.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO-98/20734	05/1998	Glenn et al.		
	BB	WO-91/01146	02/1991	Pillai et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	DENG et al., "Sustainable Cutaneous Gene Delivery", Nature Biotechnology 15:1388-1390 (1997)	
	CB	ELLIS, R. "New Technologies for Making Vaccines", Vaccines 29:568-574 (1998)	
	CC	FRIES et al., "Evidence of Fibroblast Heterogeneity and the Role of Fibroblast Subpopulations in Fibrosis", Clin. Immunol. Immunopathol. 72(3):283-292 (1994)	
	CD	GLENN et al., "Skin Immunization Made Possible by Cholera Toxin", Nature 391(6670):851 (1998)	
	CE	GLENN et al., "Transcutaneous Immunization with Cholera Toxin Protects Mice Against Lethal Mucosal Toxin Challenge", J. Immunol. 161:3211-3214 (1998)	
	CF	KONDO et al., "Epidermal Cytokines in Allergic Contact Dermatitis", J. Am. Acad. Dermatol. 33:786-800 (1995)	
	CG	LOHOFF et al., "The Th1/Th2 Paradigm and Experimental Murine Leishmaniasis", Int. Arch. Allergy Immunol. 115:191-202 (1998)	
	CH	LUGER et al., "The Role of Cytokines and Neuroendocrine Hormones in Cutaneous Immunity and Inflammation", Allergy 50:292-302 (1995)	
	CI	NASIR et al., "Contact Dermatitis. Clinical Perspectives and Basic Mechanisms", Clin. Rev. Allergy and Immunol. 14:151-184 (1996)	
	CJ	PASTORE et al., "Granulocyte Macrophage Colony Stimulating Factor is Overproduced by Keratinocytes in Atopic Dermatitis: Implications for Sustained Dendritic Cell Activation in the Skin", J. Clin. Invest. 99:3009-3017 (1997)	
	CK	PAUL et al., Transdermal Immunisation with Large Proteins by Means of Ultradeformable Drug Carriers", Eur. J. Immunol. 25:3521-3524 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	09/890,371
				Filing Date	April 8, 2002
				First Named Inventor	Gregor CEVC
				Art Unit	1646
				Examiner Name	Bruce D. Hissong
				Attorney Docket Number	0107070.00129US1
Sheet	2	of	2		

	CL	SCHATZLEIN et al., "Non-uniform Cellular Packing of the Stratum Corneum and Permeability Barrier Function of Intact Skin: a High Resolution Confocal Laser Scanning Microscopy Study Using Highly Deformable Vesicles (Transfersomes)", Br. J. Dermatol. 138:583-592 (1998)	
	CM	STRANGE et al., "Staphylococcal Enterotoxin B Applied on Intact Normal and Intact ATopic Skin Induces Dermatoma", Arch. Dermatol. 132-27-33 (1996)	
	CN	WANG et al., "Epicutaneous Exposure of Protein Antigen Induces a Predominant Th2-like Response with IgE Production in Mice" J. Immunol. 156:4079-4082 (1996)	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--